Evolution of the Average Target: Quest Diagnostics Incorporated

Evolution of the Average Target - Quest Diagnostics Incorporated

Evolution of the Target Price: Quest Diagnostics Incorporated

Evolution of the Target Price - Quest Diagnostics Incorporated

Changes in Analyst Recommendations: Quest Diagnostics Incorporated

29292f6041c468297df7307ac72663.XZ_1hTFoONWwqqVzuRuscZ1jLFdQDLDfn9UDLP6aMeo.Md2x1QEaSuCHmv0y_kP7PtQ7fCYCR_6UwOY7HaTOcKsW_KD_aQ1fpof9zg~faa8b575ae694925a6c32f7d22096e93
28/10 Evercore ISI Adjusts Price Target on Quest Diagnostics to $240 From $235 MT
27/10 Rothschild & Co Redburn Adjusts Price Target on Quest Diagnostics to $279 From $251 MT
23/10 Deutsche Bank Adjusts Quest Diagnostics PT to $245 From $232, Maintains Hold Rating MT
20/10 UBS Raises Quest Diagnostics Price Target to $250 From $245, Maintains Neutral Rating MT
08/10 Leerink Partners Adjusts Quest Diagnostics Price Target to $265 From $254 MT
06/10 Barclays Adjusts Price Target on Quest Diagnostics to $260 From $250, Keeps Overweight Rating MT
06/10 Evercore ISI Adjusts Price Target on Quest Diagnostics to $235 From $240, Keeps In Line Rating MT
22/09 Baird Adjusts Price Target on Quest Diagnostics to $260 From $255, Maintains Neutral Rating MT
21/09 Truist Raises Price Target on Quest Diagnostics to $260 From $250, Keeps Hold Rating MT
08/09 UBS Adjusts Quest Diagnostics Price Target to $245 From $232, Maintains Neutral Rating MT
31/07 Argus Research Adjusts Quest Diagnostics Price Target to $260 From $225, Maintains Buy Rating MT
28/07 JPMorgan Adjusts Price Target on Quest Diagnostics to $250 From $220, Maintains Neutral Rating MT
27/07 Rothschild & Co Redburn Adjusts Quest Diagnostics Price Target to $251 From $233, Maintains Buy Rating MT
24/07 UBS Adjusts Price Target on Quest Diagnostics to $232 From $220, Maintains Neutral Rating MT
24/07 Baird Adjusts Quest Diagnostics Price Target to $255 From $236, Maintains Neutral Rating MT
24/07 Barclays Raises Quest Diagnostics Price Target to $250 From $230, Maintains Overweight Rating MT
24/07 Mizuho Securities Adjusts Quest Diagnostics Price Target to $260 From $235, Maintains Outperform Rating MT
24/07 Deutsche Bank Adjusts Quest Diagnostics Price Target to $232 From $205, Maintains Hold Rating MT
24/07 Truist Raises Price Target on Quest Diagnostics to $250 From $225, Keeps Hold Rating MT
24/07 Morgan Stanley Adjusts PT on Quest Diagnostics to $260 From $226, Maintains Overweight Rating MT
24/07 Evercore ISI Cuts Quest Diagnostics Price Target to $240 From $225 MT
16/07 Leerink Partners Adjusts Quest Diagnostics Price Target to $244 From $240, Maintains Outperform Rating MT
18/05 Baird Adjusts Price Target on Quest Diagnostics to $232 From $229, Maintains Neutral Rating MT
27/04 Rothschild & Co Redburn Adjusts Price Target on Quest Diagnostics to $233 From $224, Maintains Buy Rating MT
23/04 UBS Adjusts Quest Diagnostics Price Target to $220 From $210, Maintains Neutral Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+4.74%
+28.38%
+1.73%
-3.07%
+21.74%
-1.6%
+6.67%
+19.07%
+31.24%
+46.23%
Average +15.51%
Weighted average by Cap. +13.03%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
245.62USD
Average target price
257.27USD
Spread / Average Target
+4.74%
High Price Target
279.00USD
Spread / Highest target
+13.59%
Low Price Target
235.00USD
Spread / Lowest Target
-4.32%

Analyst Consensus Detail

Analyst consensus - Quest Diagnostics Incorporated

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Quest Diagnostics Incorporated
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Quest Diagnostics Incorporated
  1. Stock Market
  2. Stocks
  3. DGX Stock
  4. Consensus Quest Diagnostics Incorporated